NCT07498244 Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients
| NCT ID | NCT07498244 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Graz |
| Condition | Pulmonary Hypertension Due to Lung Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2026-07-01 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic lung diseases such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension. This serious complication involves increased pressure in the lung vessels, which strains the heart and worsens outcomes. Since the early symptoms are unclear, diagnosis often occurs too late, underscoring the need for simple, noninvasive methods of early detection. A key driver of the disease is vascular remodeling, which involves the narrowing and stiffening of blood vessels. This process involves changes in the extracellular matrix, particularly in the understudied basement membrane. Our project examines how specific components, especially non-classical collagens, change during disease progression. As vessels remodel, detectable fragments enter the bloodstream, potentially creating a molecular fingerprint of the disease. By analyzing lung tissue and blood samples, the investigators aim to identify non-invasive biomarkers for earlier diagnosis, better patient classification, and more personalized treatment.
Eligibility Criteria
Inclusion criteria: Patients undergoing lung transplantation with COPD or PF, with or without associated PH and PAH. \- Outpatient cohort with COPD or PF, with or without associated PH or PAH. Exclusion criteria: * Presence of other lung diseases * Signs of infection, such as pneumonia, pulmonary tuberculosis, or pleural effusions.
Contact & Investigator
Nikolaus Kneidinger, MD
STUDY CHAIR
Medical University of Graz
Frequently Asked Questions
Who can join the NCT07498244 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Hypertension Due to Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07498244 currently recruiting?
Yes, NCT07498244 is actively recruiting participants. Contact the research team at grazyna.kwapiszewska-marsh@medunigraz.at for enrollment information.
Where is the NCT07498244 trial being conducted?
This trial is being conducted at Graz, Austria.
Who is sponsoring the NCT07498244 clinical trial?
NCT07498244 is sponsored by Medical University of Graz. The principal investigator is Nikolaus Kneidinger, MD at Medical University of Graz. The trial plans to enroll 80 participants.